FDA Approves Benicar for the Hypertension Treatment in Children and Adolescents 6-16 old

FDA Approves Benicar for the Hypertension Treatment in Children and Adolescents 6-16 old.


US Food and Drug Administration (FDA) has approved the care of capital blood urge Benicar (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age suprax cost. Benicar was from the word go approved in 2002 for the curing of hypertension in adults.



Approximately 5 percent, or 3,6 million, American children go through from pongy blood pressure, with the adulthood incognizant they have the condition. Studies have also found that the standard blood influence of American children is on the rise, in complementarity with the increase of children's weight clobetasol propiona ointment usp,005. In fact, an breakdown of nearly 40 years of subject surveys of high blood press trends in children and adolescents showed that the prevalence of raised blood pressure among this group has been growing since the last 1980's.



A "As hypertension is on the go uphill also in a younger population, Daiichi Sankyo believes it is superior to help doctors meet the test of treating these pediatric patients by providing a remedying option to help people effectively undertake their hypertension," said Reinilde Heyrman, MD, Vice President Clinical Development - Operations, Daiichi Sankyo Pharma Development.



Pediatric hypertension is closely linked to babyhood obesity, as abdominous children are at approximately a three-fold higher endanger for hypertension than non-obese children. Additionally hypertension during boyhood has been shown to be an unprejudiced chance factor for hypertension in adulthood, and to be associated with anciently markers of cardiovascular disease, making it critical to treat this teach in children and adolescents.